Cost-Effectiveness Analysis of Bevacizumab- Paclitaxel-Carboplatin (PC) Versus PC in First-Line Therapy of Advanced Non-Small Cell Lung Cancer from Patients' Perspective in Vietnam
Abstract
Authors
T.T.H. Tran T.T.T. Nguyen
T.T.H. Tran T.T.T. Nguyen
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now